Laferobion suppositories 150000 IU 1g. №10

Description

Laferobion №10 Composition
active substance: interferon alfa-2b

1 suppository contains: recombinant human interferon alpha-2b – 150,000 IU;

excipients: refined sunflower oil, tocopherol acetate, sodium ascorbate, ascorbic acid, solid fat.

Laferobion №10 Dosage form
Suppositories.

Basic physical and chemical properties: suppositories of spherical shape, yellowish-white, uniform consistency.

Laferobion №10 Pharmacotherapeutic group
Immunostimulants. Interferons. Interferon alpha-2b.

ATX code L03A B05.

Pharmacodynamics
Interferon alfa-2b recombinant has a pronounced antiviral, antiproliferative and immunomodulatory effect. The active ingredient of Laferobion® – interferon alfa-2b recombinant – has an immunomodulatory effect on T- and B-lymphocytes, normalizes the content of immunoglobulin E, and has antiviral activity. Antibodies that neutralize the antiviral activity of recombinant interferon alpha-2b are not formed, even when it is used for 2 years, the functioning of the endogenous system is normalized.

Pharmacokinetics
The pharmacokinetic properties of recombinant interferon alpha-2b are poorly understood.

Indications
For children in the complex therapy of acute respiratory viral infections (ARVI).

Laferobion Contraindications
Hypersensitivity to the components of the drug; presence of thyroid dysfunction in the patient; the presence of severe visceral disorders in patients with Kaposi’s sarcoma; severe cardiovascular disease; psoriasis, severe liver and / or kidney dysfunction; epilepsy and other diseases of the central nervous system (including functional); chronic hepatitis against the background of progressive or decompensated liver cirrhosis; chronic hepatitis in patients receiving or have recently received immunosuppressive therapy (other than a short course of corticosteroids); a history of autoimmune hepatitis or other autoimmune diseases. Inhibition of the myeloid germ of hematopoiesis.

Interaction with other medicinal products and other types of interactions
The drug should be used with caution in conjunction with opioid drugs, analgesics, hypnotics and sedatives (potentially causing a myelosuppressive effect).

With simultaneous use with drugs that are metabolized by oxidation (including with xanthine derivatives – aminophiline and theophylline), the possibility of the effect of Laferobion® on oxidative metabolic processes should be taken into account. The concentration of theophylline in the blood serum must be monitored and, if necessary, the dosage regimen must be adjusted.

When using the drug in combination with chemotherapeutic drugs (cytarabine, doxorubicin, teniposide, cyclophosphamide), the risk of developing life-threatening toxic effects (their severity and duration) increases.

With simultaneous use with zidovudine, the risk of developing neutropenia increases.